The chances of hepatic resection curing hepatocellular carcinoma

被引:60
作者
Cucchetti, Alessandro [1 ,2 ]
Zhong, Jianhong [3 ]
Berhane, Sarah [4 ]
Toyoda, Hidenori [5 ]
Shi, KeQing [6 ]
Tada, Toshifumi [5 ]
Chong, Charing C. N. [7 ]
Xiang, Bang-De [3 ]
Li, Le-Qun [3 ]
Lai, Paul B. S. [7 ]
Ercolani, Giorgio [1 ,2 ]
Mazzaferro, Vincenzo [8 ,9 ]
Kudo, Masatoshi [10 ]
Cescon, Matteo [1 ]
Pinna, Antonio Daniele [1 ]
Kumada, Takashi [11 ]
Johnson, Philip J. [12 ]
机构
[1] Univ Bologna, Dept Med & Surg Sci, Alma Mater Studiorum, Bologna, Italy
[2] Morgagni Pierantoni Hosp, Forli, Italy
[3] Guangxi Med Univ, Affiliated Tumour Hosp, Dept Hepatobiliary Surg, Nanning, Peoples R China
[4] Univ Liverpool, Dept Biostat, Liverpool, Merseyside, England
[5] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Gifu, Japan
[6] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatol, Wenzhou, Peoples R China
[7] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China
[8] Univ Milan, Milan, Italy
[9] Fdn IRCCS, Ist Nazl Tumori, Gastrointestinal Surg & Liver Transplantat Unit, Milan, Italy
[10] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan
[11] Ogaki Municipal Hosp, Ogaki Womens Coll, Dept Gastroenterol & Hepatol, Gifu, Japan
[12] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England
关键词
Hepatocellular carcinoma; Recurrence; Hepatic resection; Cure fraction; Relative survival; SUSTAINED VIROLOGICAL RESPONSE; CURE FRACTION; SURVIVAL; CANCER; COMORBIDITY; CIRRHOSIS; TOOL;
D O I
10.1016/j.jhep.2019.11.016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: The popular sense of the word "cure" implies that a patient treated for a specific disease will return to have the same life expectancy as if he/she had never had the disease. In analytic terms, it translates into the concept of statistical cure which occurs when a group of patients returns to having similar mortality to a reference population. The aim of this study was to assess the probability of being cured from hepatocellular carcinoma (HCC) by hepatic resection. Methods: Data from 2,523 patients undergoing resection for HCC were used to fit statistical cure models, to compare disease-free survival (DFS) after surgery to the survival expected for patients with chronic hepatitis and/or cirrhosis and the general population, matched by sex, age, race/ethnicity and year of diagnosis. Results: The probability of resection enabling patients with HCC to achieve the same life expectancy as those with chronic hepatitis and/or cirrhosis was 26.3%. The conditional probability of achieving this result was time-dependent, requiring about 8.9 years to be accomplished with 95% certainty. Considering the general population as a reference, the cure fraction decreased to 17.1%. Uncured patients had a median DFS of 1.5 years. In multivariable analysis, patient's age and the risk of early HCC recurrence (within 2 years) were independent determinants of the chance of cure (p <0.001). The chances of being cured ranged between 36.0% for individuals at low risk of early recurrence to approximately 3.6% for those at high risk. Conclusion: Estimates of the chance of being cured of HCC by resection showed that cure is achievable, and its likelihood increases with the passing of recurrence-free time. The data presented herein can be used to inform decision making and to provide patients with accurate information. Lay summary: Data from 2,523 patients who underwent resection for hepatocellular carcinoma were used to estimate the probability that resection would enable treated patients to achieve the same life expectancy as patients with chronic hepatitis and/or cirrhosis, and the general population. Herein, the cure model suggests that in patients with hepatocellular carcinoma, resection can enable patients to achieve the same life expectancy as those with chronic liver disease in 26.3% of cases and as the general population in 17.1% of cases. (C) 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:711 / 717
页数:7
相关论文
共 31 条
[1]   EM algorithms for fitting multistate cure models [J].
Beesley, Lauren J. ;
Taylor, Jeremy M. G. .
BIOSTATISTICS, 2019, 20 (03) :416-432
[2]   Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial [J].
Bruix, Jordi ;
Takayama, Tadatoshi ;
Mazzaferro, Vincenzo ;
Chau, Gar-Yang ;
Yang, Jiamei ;
Kudo, Masatoshi ;
Cai, Jianqiang ;
Poon, Ronnie T. ;
Han, Kwang-Hyub ;
Tak, Won Young ;
Lee, Han Chu ;
Song, Tianqiang ;
Roayaie, Sasan ;
Bolondi, Luigi ;
Lee, Kwan Sik ;
Makuuchi, Masatoshi ;
Souza, Fabricio ;
Le Berre, Marie-Aude ;
Meinhardt, Gerold ;
Llovet, Josep M. .
LANCET ONCOLOGY, 2015, 16 (13) :1344-1354
[3]   Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population [J].
Bruno, Savino ;
Di Marco, Vito ;
Iavarone, Massimo ;
Roffi, Luigi ;
Crosignani, Andrea ;
Calvaruso, Vincenza ;
Aghemo, Alessio ;
Cabibbo, Giuseppe ;
Vigano, Mauro ;
Boccaccio, Vincenzo ;
Craxi, Antonio ;
Colombo, Massimo ;
Maisonneuve, Patrick .
JOURNAL OF HEPATOLOGY, 2016, 64 (06) :1217-1223
[4]   Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection [J].
Chan, Anthony W. H. ;
Zhong, Jianhong ;
Berhane, Sarah ;
Toyoda, Hidenori ;
Cucchetti, Alessandro ;
Shi, KeQing ;
Tada, Toshifumi ;
Chong, Charing C. N. ;
Xiang, Bang-De ;
Li, Le-Qun ;
Lai, Paul B. S. ;
Mazzaferro, Vincenzo ;
Garcia-Finana, Marta ;
Kudo, Masatoshi ;
Kumada, Takashi ;
Roayaie, Sasan ;
Johnson, Philip J. .
JOURNAL OF HEPATOLOGY, 2018, 69 (06) :1284-1293
[5]   Comorbidity-Adjusted Life Expectancy: A New Tool to Inform Recommendations for Optimal Screening Strategies [J].
Cho, Hyunsoon ;
Klabunde, Carrie N. ;
Yabroff, K. Robin ;
Wang, Zhuoqiao ;
Meekins, Angela ;
Lansdorp-Vogelaar, Iris ;
Mariotto, Angela B. .
ANNALS OF INTERNAL MEDICINE, 2013, 159 (10) :667-+
[6]   Prognostic factors for hepatocellular carcinoma recurrence [J].
Colecchia, Antonio ;
Schiumerini, Ramona ;
Cucchetti, Alessandro ;
Cescon, Matteo ;
Taddia, Martina ;
Marasco, Giovanni ;
Festi, Davide .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (20) :5935-5950
[7]  
Council of European Union European Parliament, GEN DAT PROT REG EU
[8]   Cure Model Survival Analysis After Hepatic Resection for Colorectal Liver Metastases [J].
Cucchetti, Alessando ;
Ferrero, Alessandro ;
Cescon, Matteo ;
Donadon, Matteo ;
Russolillo, Nadia ;
Ercolani, Giorgio ;
Stacchini, Giacomo ;
Mazzotti, Federico ;
Torzilli, Guido ;
Pinna, Antonio Daniele .
ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (06) :1908-1914
[9]   Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients [J].
Cucchetti, Alessandro ;
Sposito, Carlo ;
Pinna, Antonio Daniele ;
Citterio, Davide ;
Cescon, Matteo ;
Bongini, Marco ;
Ercolani, Giorgio ;
Cotsoglou, Christian ;
Maroni, Lorenzo ;
Mazzaferro, Vincenzo .
WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (08) :1469-1476
[10]   Improved Diagnostic Imaging and Interventional Therapies Prolong Survival After Resection for Hepatocellular Carcinoma in Cirrhosis: The University of Bologna Experience Over 10 Years [J].
Cucchetti, Alessandro ;
Zanello, Matteo ;
Cescon, Matteo ;
Ercolani, Giorgio ;
Del Gaudio, Massimo ;
Ravaioli, Matteo ;
Grazi, Gian Luca ;
Pinna, Antonio D. .
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (06) :1630-1637